pentoxifylline has been researched along with Dyslipidemias in 2 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake." | 5.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake." | 1.43 | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. ( Chang, ML; Chao, J; Cheng, HY; Liao, JW; Pao, LH; Peng, WH; Ye, JH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elseweidy, MM | 1 |
| Mohamed, HE | 1 |
| Elrashidy, RA | 1 |
| Atteia, HH | 1 |
| Elnagar, GM | 1 |
| Ye, JH | 1 |
| Chao, J | 1 |
| Chang, ML | 1 |
| Peng, WH | 1 |
| Cheng, HY | 1 |
| Liao, JW | 1 |
| Pao, LH | 1 |
2 other studies available for pentoxifylline and Dyslipidemias
| Article | Year |
|---|---|
Inhibition of Aortic Calcification by Policosanol in Dyslipidemic Rabbits Is Enhanced by Pentoxifylline: Potential Role of PCSK9.
Topics: Alkaline Phosphatase; Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Biomarkers; Bone Mo | 2018 |
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dyslipidemias; Fa | 2016 |